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ABSTRACT
Sporadic late-onset AD (LOAD) is the most common form of dementia (Woods et
al, 2020). In recent years, significant attention has been given to the role of infection in
the pathogenesis of late-onset AD/dementia. The Cpn pathogen has been an organism of
particular focus following the seminal study Balin et. al 1998 which found that Cpn DNA
was present in 90% of brains from patients diagnosed with LOAD. Subsequent
immunohistochemical studies demonstrated that Cpn antigens were present in the frontal
and temporal cortices of LOAD brains and that Aβ amyloid plaques found in those
regions of the brain co-localize with areas of Cpn immunoreactivity (Hammond et al
2010).
This study aims to quantitate Chlamydia pneumoniae (Cpn) antigen(s) and Aβ
amyloid plaques throughout the limbic system and cortical areas of brains from
individuals diagnosed with late-onset Alzheimer’s disease (AD)/dementia and from
individuals diagnosed with non-demented conditions. It was expected that the load of
Cpn will positively correlate with the load of amyloid plaques in the brains investigated.
Furthermore, as it is well established that amyloid plaques are a hallmark of Alzheimer’s
disease pathology, it is assumed that the load of amyloid plaques and Cpn inclusions will
be greater in the brains of individuals diagnosed with AD/dementia compared to the load
of amyloid plaques and Cpn inclusions in brains from individuals not diagnosed with
AD/dementia.
Sections of the hippocampus and the prefrontal cortex were dissected and
processed for immunostaining from the eight cadaver brains that had been donated to the
Pennsylvania Human Gifts Registry. The brains selected included an equal number of
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brains with confirmed dementia/AD and brains with no diagnosis of AD/dementia.
AD/dementia or non-AD/dementia status was determined based on the listed cause of
death (COD. Five sections from the hippocampus and the prefrontal cortex were
immunolabeled with specific antibodies for amyloid plaques and Cpn and then digitally
imaged at 40X. The Cpn inclusions and amyloid plaques were counted in each region and
normalized using the equivalent total area/section. The data was recorded as mean counts
per brain section. The AD/dementia brains showed a load of 1854.00±210.31 amyloid
plaques and a load of 2272.75±395.72 Cpn inclusions in the hippocampus. The
AD/dementia prefrontal cortex displayed a load of 3793.75±997.02 amyloid plaques and
a load of 1833.25±470.02 Cpn inclusions The non-AD/dementia brains showed a load of
263.00±223.06 amyloid plaques and a load of 332.00±220.30 Cpn inclusions in the
hippocampus. The non-AD/dementia prefrontal cortex displayed a load of 970.25±636.08
amyloid plaques and a load of 424.75±324.22 Cpn inclusions.
This preliminary study yielded data of an association between amyloid pathology
and infection by Cpn in both AD/demented and non-AD/dementia brains. It was revealed
that the load of Cpn does correlate with the load of amyloid plaques in all brains where
amyloid plaque pathology was present. Furthermore, the load of amyloid plaques and
Cpn inclusions were substantially greater in brains with an AD/dementia diagnosis
compared to brains without and AD/dementia diagnosis. These data help to support prior
work demonstrating a relationship between infection and LOAD pathology. Furthermore,
this study demonstrated that the Human Gifts registry is a viable and valuable resource of
tissue for research purposes.
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INTRODUCTION
1.1 Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia, affecting nearly
55 million individuals worldwide. This number is projected to double every 20 years due
to the global trend of population aging. According to a 2017 estimate, by 2050 the
worldwide incidence of AD is projected to reach 139 million individuals, representing 2.5
times increase in global cases (Guerchet et al, 2020). Furthermore, there is currently no
cure or reliable prevention measures for AD. Several prescription drugs are available for
symptom management of AD, largely acetylcholinesterase inhibitors, but these drugs
only affect a modest improvement in cognition and do not slow disease progression or
delay disease onset (Cummings, 2021). Thus, AD represents a major social, health, and
economic burden to the caretakers and society.
AD is classified into two main types: early onset AD (EOAD) and late onset AD
(LOAD). The two subtypes can be immediately distinguished by age of onset, with the
first symptoms of EOAD occurring before the age of 65 and the first symptoms of LOAD
occurring after the age of 65 (Bertram et al, 2010; Goate & Hardy, 2012). EOAD and
LOAD can be further categorized by what is understood of their underlying causes.
EOAD, is familial and thus largely genetic in origin (Bertram et al, 2010). EOAD has
been strongly linked to mutations in the genes APP, PSEN1, and PSEN2, which code for
amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2)
respectively (Gonneaud et al, 2021). Additionally, EOAD accounts for ~5% of all AD
cases. In contrast LOAD, which makes up the remaining of ~95% of AD cases, is not
associated with any specific mutations or conditions and it is thus not currently possible
to predict LOAD development with any appreciable degree of certainty (Goate & Hardy,
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2012; Gonneaud et al, 2021). LOAD has been associated with a variety of risk factors
such as age (Guerrero et al, 2021), a family history of LOAD (Gonneaud et al, 2021),
expression of Apolipoprotein E4 (Gerard, 2007; Gonneaud, 2021), quality of diet,
amount of physical activity, and presence of healthy social relationships (Parker & Rhee,
2021). The development of LOAD is therefore conceptualized as the result of the
complex interactions of several genetic and environmental factors. Despite the
differences in the presentation and likely cause, both EOAD and LOAD express the same
neuropathological characteristics. These characteristics include the presence of
extracellular deposits of amyloid-β (Aβ) plaques and intracellular deposits of
neurofibrillary tangles (NFTs) in cortical neurons (Woods et al, 2020).
1.2 Amyloid Precursor Protein and Aβ-Plaque Formation
Aβ plaques are composed of aggregated species of Aβ peptides. These peptides
are derived from the sequential enzymatic breakdown of amyloid precursor protein (APP)
(Tan et al. 2009). APP is a large type 1 transmembrane protein that is highly expressed in
the brain. APP, along with amyloid precursor like protein 1 (APLP1) and amyloid
precursor like protein 2 (APLP2), form the mammalian APP gene family. These amyloid
precursor proteins form a group of phylogenetically ancient and highly conserved
proteins which have important physiological roles in the CNS and PNS. The role of these
proteins is not currently defined, but the APP family is associated with nervous system
development, the formation and function of the neuromuscular junction, synaptogenesis,
dendritic complexity and spine density, axonal growth and guidance, and synaptic
functions, including synaptic plasticity, learning and memory (Muller et al, 2017).
APP is notable among this group as it is the only APP gene family protein which
contains the Aβ peptide sequence necessary for the formation of Aβ plaques (Muller et al,
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2017; Guo et al, 2020). Enzymatic processing of APP can be categorized into two
pathways; amyloidogenic and non-amyloidogenic (Wilkins & Swerdlow, 2017; Wilquet
& De Strooper, 2004). The non-amyloidogenic pathway is initiated by the action of the αsecretase A-disintegrin and metalloproteinase domain-containing protein 10 (ADAM10).
ADAM10 cleaves APP in the ectodomain at a site within the Aβ peptide sequence, thus
splitting Aβ between two APP fragments. The first fragment is a soluble peptide sAPPα,
which is shed into the extracellular (EC) space, and the second fragment is a carboxy
terminal fragment α-Carboxy terminal fragment (α-CTF) which remains embedded in the
cell membrane. α-CTF is further cleaved by γ-secretase, a multiprotein complex
composed of either Presenilin 1 (PSEN1) or Presenilin 2 (PSEN2), which is the catalytic
unit of the protease, nicastrin (NCSTN), anterior pharynx defensive phenotype 1 (Aph-1),
and presenilin enhancer-2 (PEN2). Cleavage of α-CTF by γ-secretase results in
production of APP intracellular domain (AICD), which is released into the cytoplasm,
and the p3 peptide, a non-toxic form of amyloid which is shed into the EC space. The
majority of human APP processing occurs down the non-amyloidogenic pathway
(Wilkins & Swerdlow, 2017; Steiner et al, 2018; O’Brien et al, 2011).
The amyloidogenic pathway is initiated by the action of the β-secretase beta-site
APP cleaving enzyme 1 (BACE1). Like ADAM10, BACE1 cleaves APP in the
ectodomain splitting APP into two fragments, sAPPβ, a soluble peptide which is shed
into the EC space, and β-CTF, which remains embedded into the cell membrane.
However, unlike ADAM10, BACE1 cleaves APP at the amino terminus of the Aβ
peptide rather than within the peptide itself. Thus, the resulting membrane embedded βCTF fragment contains a complete Aβ peptide sequence. β-CTF is then cleaved by γsecretase producing AICD which, as in the non-amyloidogenic pathway, is released into
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the cytoplasm and the Aβ peptide which is released into the EC space (Al-Atrache at al,
2019; Wilkins & Swerdlow, 2017; Steiner et al, 2018; O’Brien et al, 2011). The Aβ
peptides produced by γ-secretase processing range from 37 to 43 amino acid residues in
length, with Aβ40 accounting for the vast majority of peptides produced followed
distantly by Aβ42. The remaining possible Aβ peptide lengths occur only in relatively
small amounts. This variance in Aβ peptide length occurs as γ-secretase processes β-CTF
in sequential tripeptide-releasing cleavages which may begin at several possible points on
the protein. The first cut in the process is referred to as the ε-cleavage, followed by the ζcleavage, and finally the γ-cleavage, although not all Aβ peptides require three cuts. The
cleavage sites are further defined by reference to the amino acid residue where the cut
occurs. For example, in the generation of Aβ40 the first cut occurs at residue 49, followed
by residue 46, and finally residue 43. Thus, the pathway would be completely defined as
ε-49, ζ-46 and ɣ-43. Aβ42 is generated through the pathway ε-48 and ζ-45 (Steiner et al
2018; Qiu et al, 2015).
Although Aβ40 constitutes the vast majority of species produced by the
amyloidogenic pathway, Aβ42 is primarily responsible for the formation of amyloid
plaques in AD. The monomeric form of Aβ42 initially produced by the proteolytic
breakdown of APP is not known to be cytotoxic or otherwise disruptive to neuronal
functioning and may in fact play a role in normal physiological processes. Issues arise,
however, if the Aβ42 that accumulates in the neuropil misfolds (Zhou et al, 2012,
Verman, 2015). Many factors have been identified as possible triggers for misfolding,
such as oxidative stress, glycation, and mutation, but no specific factor or combination of
factors has been directly implicated. Misfolded Aβ42 monomers are capable of
aggregating into oligomers. These oligomers may organize into protofibrils and
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eventually into mature fibrils. Once a critical concentration of mature Aβ42 fibrils has
been reached a secondary nucleation reaction occurs. In this reaction, the mature fibrils
act as a template and catalyst for the formation of additional oligomers from misfolded
Aβ42. Thus, a positive feedback loop is created in which oligomers organize into fibrils
which then promote the formation of more oligomers. Both the mature fibrils and the
oligomers are known to exert a cytotoxic effect, however the Aβ42 oligomers are
considered to be the major driver of neurotoxic damage in AD (Tamango et al 2018;
Verma et al, 2015). Ex vivo studies of Aβ42 oligomers have shown that it may trigger
invagination and pore formation in the lipid bilayer, dysregulation of calcium
homeostasis, stimulation of an inflammatory response, induction of oxidative stress
through the formation of metal-Aβ42 complexes, depress synaptic transmission through
interference of glutaminergic receptors, induction of apoptosis through the impairment of
autophagy mechanisms, and competitively bind to cell surface receptors (Zhao et al,
2012; Mucke & Selkoe, 2012; Tamagno et al; 2018; Verma et al, 2015).
1.3 Neurofibrillary Tangles (NFTs)
NFTs are aggregates of hyperphosphorylated tau. Tau is a highly soluble and
intrinsically disordered microtubule-associated protein (MAP) that is found mainly in
neurons. Like all MAPs, tau is associated with the formation and stabilization of neuronal
microtubule networks as well as the regulation of axon growth (Barage & Sonawane,
2015; Wegmann et al, 2021). Tau is composed of 4 domains: the N-terminal domain, the
proline rich domain, the microtubule binding domain, and the C-terminal domain. Due to
alternative splicing, primarily within the N-terminal and microtubule binding domains,
several isoforms of tau exist. Six of the isoforms are found specifically in the CNS. The
six tau isoforms of the CNS are further classified by the number of repeats found within
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the microtubule binding domain. Three of the isoforms contain 3 repeating microtubule
binding domains and are referred to as 3-repeat (3R) tau while the remaining three
isoforms contain 4 repeating microtubule binding domains and are referred to as 4-repeat
(4R) tau. The 4R tau has greater microtubule binding affinity than 3R tau due to the
additional binding domain repeat (Jouanne et al, 2017; Naseri et al, 2019). These two
isoform groups exist in a 1:1 ratio in adult human brains, and disruption of this ratio has
been implicated in a variety of tauopathies, including AD.
Tau’s affinity to bind to microtubules is regulated through post-translational
phosphorylation by the enzymes glycogen synthase kinase 3 (GSK-3β) and cyclindependent kinase 5 (cdk5). Specifically, as tau becomes increasingly phosphorylated its
affinity for microtubule binding decreases. Tau is normally phosphorylated at specific
serine, threonine and tyrosine residues found mostly within the proline rich domain.
Under pathological conditions, tau becomes phosphorylated at additional residue sites not
indicated in normal tau functioning. Thus, tau that is hyperphosphorylated possesses 3 to
4 times more phosphates per mole than normally functioning tau. In addition to losing the
ability to bind to microtubules, hyperphosphorylated tau will polymerize into twisted
double stranded fibrils called paired helical filaments (PHFs). It is these PHFs which
aggregate to form NFTs (Appelt et al, 1993; Wang J-Z et al, 2013; Jouanne et al, 2017;
Morris et al, 2011). The loss of normal tau function and the subsequent formation of
NFTs compromises the structural integrity and regulatory functions of the cytoskeleton
which results in abnormal cell morphology, compromised axonal transport, disruption of
synaptic dysfunction, and ultimately neurodegeneration (Barage & Sonawane, 2015;
Wegmann et al, 2021).
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1.6 Amyloid Cascade Hypothesis
The amyloid cascade hypothesis has been the predominant theory for describing
the pathology of AD for the past few decades (Balin et al, 2018; Garbuz et al, 2020).
Under this theory, the neuropathological characteristics of AD may be due to a series of
events triggered by the abnormal accumulation of Aβ plaques (Barage & Sonawane,
2015; Balin et al, 2018). For example, it has been demonstrated that Aβ oligomers can
trigger the hyper-phosphorylation of tau through activation of neuron surface receptors
and thus promote the formation of NFTs (Zhang et al, 2020; Garbuz et al, 2020). Aβ
plaque accumulation has also been shown to induce chronic neuroinflammation which
can result in neurodegeneration via apoptosis and necrosis of neurons (Carrero et al,
2012; Garbuz et al, 2020). Furthermore, Aβ plaques have been implicated in the
disturbance of neural membrane potential, the cholinergic system, an increase in CNS
oxidative stress, and the formation of neurites, all of which may further contribute to the
neurodegeneration of AD (Barage & Sonawane, 2015; Garbuz et al, 2020).
1.7 Inflammation and LOAD
Neuroinflammation is strongly connected with the development of LOAD
pathology (Garbuz et al, 2020; Lee et al, 2008). Neuroinflammation itself is primarily
mediated by the action of microglia and astrocytes (Di Sabato et al, 2017). As such,
activated microglia and astrocytes are typical characteristics of LOAD pathology (Garbuz
et al, 2020). When activated, these cell types release a variety of inflammatory agents,
such as pro-inflammatory cytokines, reactive oxygen species, and complement proteins,
as a matter of their normal functioning. However, chronic activation of microglia and
astrocytes, and by extension chronic exposure to these inflammatory agents, can result in
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neuronal damage and cell death typical of neurodegenerative diseases such as AD (Dheen
et al, 2007; González-Reyes et al, 2017). For example, it has been demonstrated that mice
which have been genetically modified to over produce astrocyte derived IL-6 develop
progressive neurodegeneration by 6 months of age (Garbuz et al, 2020). Studies have
shown that the probability of developing LOAD correlates with allele variants of genes
involved in regulating the immune response (Garbuz et al, 2020; Millington et al, 2014).
There is also evidence that pro-inflammatory cytokines associated with microglia
and astrocyte activation may induce an increase in the production of Aβ plaques
(González-Reyes et al, 2017). Cytokines IL-1, IL-6, tumor necrosis factor-α (TNF-α) and
Transforming growth factor-β (TGF-β) have been implicated in the promotion of APP
synthesis and the up regulation of β-secretase, an enzyme partly responsible for the
production of Aβ 1-42. (Al-Atrache, 2019; Lee et al, 2008). Additionally, the long-term
use of nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to delay the
onset of AD but does not modify LOAD after the manifestation of clinical symptoms.
This implicates inflammation as possessing a key role in the initiation of LOAD
pathology (Balin et al, 2020; Millington et al, 2014).
1.4 Infection and LOAD
As mentioned previously, the specific etiology of LOAD is unknown. Of
particular interest in recent years has been the connection between AD and infection by
certain pathogens. Cytomegalovirus (CMV), herpes simplex virus type 1 (HSV1),
Borrelia burgdorferi, and Cpn have each been implicated in LOAD etiology (Bu et al,
2014; Al-Atrache et al, 2019). CMV DNA has been found in the serum of AD individuals
at a significantly higher rate than non-AD individuals (Khodamoradi, 2021). Infection by
CMV has also been associated with a two-fold increase in the incidence rate of dementia
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(Lee et al, 2019). HSV1 DNA has also been found at a significantly higher rate in the
serum of AD individuals (Khodamoradi et al, 2021), as well as within the AD plaques
themselves (Wozniak et al, 2008). CNS infection by HSV1 has been shown to disrupt
normal glial cell functioning which compromises the homeostatic and immune roles of
these cells, and which may promote AD pathology (Mielcarska, 2021). The presence of
B. burgdorferi IgG has been shown to increase the risk of developing AD (HerreraLandero et al, 2019). Furthermore, it has been demonstrated that B. burgdorferi is present
in AD brain tissue via PCR, immunofluorescence, and confocal microscopy and that
areas of B. burgdorferi immunoreactivity co-localize with Aβ plaques (Senejani et al,
2021).
Cpn was initially implicated in connection to LOAD etiology in a seminal study
by Balin et. al in 1998. It was found that Cpn DNA was present in 90% of brain samples
taken from patients diagnosed with LOAD. Additionally, the study demonstrated that
astrocytes, microglia, and neurons infected with Cpn co-localized with areas of AD
neuropathology (Balin et al, 1998; Woods et al, 2020). Subsequent studies (Mahoney et
al, 2000; Gerard et al, 2006) confirmed the presence of Cpn DNA is in brain regions of
LOAD patients which exhibit AD neuropathology. Mahoney et al also confirmed the role
of microglial cells as reservoirs of Cpn infection and thus as potential focal points of AD
neuropathology. Additionally, studies have implicated Chlamydia pneumoniae’s
involvement in promoting the pro-amyloidogenic pathway of APP processing through the
upregulation of expression and activity of β-secretase, upregulated expression of γsecretase, and decreased activity of α-secretase in human astrocytes (Altrache et al,
2019). Other studies have demonstrated a correlation between the presence of Cpn in
cerebrospinal fluid (Paradowski et al, 2007) and between serum anti-Cpn antibodies (Bu
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et al, 2015) to AD status. Immunohistochemical have demonstrated that Cpn antigens
correlate with AD pathology in the frontal and temporal cortices of LOAD patients
(Hammond et al, 2010) and in the brains of Cpn inoculated mice studies (Little et al,
2004; Little et al, 2014). The mouse studies (Little 2004; Little, 2014) further
demonstrated a possible causal role of Cpn in Aβ plaque formation. Recently, a robust
study from Taiwan utilizing data from the nation’s national health service has shown that
individuals who have been hospitalized with Cpn pneumonia have a significantly higher
risk of developing AD (Ou et al, 2021).
The connection between Cpn infection and LOAD pathology is currently
controversial as several studies seeking to validate or expand upon Balin et al’s initial
findings failed to find evidence (Balin et al, 2018). Such negative results have been
produced from studies regarding PCR analysis (Nochlin et al., 1999; Ring & Lyons,
2000; Taylor et al., 2002; Wozniak et al., 2003), immunohistochemistry (Nochlin et al.,
1999; Taylor et al., 2002), and serum anti-Cpn antibody detection (Ecemis et al., 2010;
Loeb et al., 2004; Yamamoto et al., 2005). However, it should be noted that among the
negative studies that sought to replicate aspects of the original study, none used the same
methodology as Balin and colleagues (Balin et al, 2018; Woods et al, 2020).
Furthermore, many of the studies which show no association are possibly underpowered
(Woods et al, 2020).
1.5 Chlamydia pneumoniae
Chlamydia pneumoniae (Cpn) is a globally ubiquitous obligate intracellular gramnegative bacterium that acts primarily as a pathogen of the respiratory tract (Balin et al,
1998, 2018). Like all species of Chlamydia, Cpn has a biphasic life cycle which
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alternates between an infectious form and a metabolically active form of the bacterium.
The infectious form, referred to as an elementary body (EB), attaches to host cells and
promotes entry. Like most intracellular pathogens, Cpn EBs form a membrane bound
vacuole as they enter the cell. Formation of this vacuole, referred to as a chlamydial
inclusion, allows for the creation of an intracellular niche which provides an environment
for the replication and release of the bacteria. Cpn will remain inside this vacuole for the
duration of the intracellular portion of its life cycle (Contini, 2010; Moore, 2014). Once
established in the inclusion, the EBs differentiate into the metabolically active form of
Cpn referred to as the reticulate bodies (RBs). The RBs undergo several rounds of
reproduction via binary fission before re-forming into EBs. The EBs are then released via
cell lysis, and the process repeats (Balin et al, 2018; Contini et al, 2010). Under normal
circumstances, the RBs will multiple and differentiate into EBs over a period of 48-72
hours (Deniset et al, 2010; Kern et al, 2009). Mouse models investigating the course of
Cpn induced pneumonia demonstrated that live bacteria could be recovered from the
lungs up 48 days post infection and lung pathology was recorded to persist up to 60 days
post infection (Yang et al, 1993). Cpn is however capable of diverting from its normal
life cycle under certain conditions. If an RB is exposed to stressful stimuli, such as the
presence of penicillin or pro-inflammatory cytokines, the metabolism of the bacteria
slows and both replication and differentiation halt. Cpn can exist in the body in this state
of quiescent for decades resulting in a state of chronic infection referred to as persistence
(Balin et al, 2018; Contini et al, 2010).
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1.8 Cpn as a causative agent of LOAD
As is the case with all chlamydial infections, infection by Cpn promotes the
secretion of pro-inflammatory cytokines by the immunocompetent cells of the CNS in
response to outer membrane proteins, heat shock proteins, and lipopolysaccharides (LPS)
(Balin et al, 2018; Contini et al, 2010). LPS is particularly implicated in the
inflammation caused by bacterial infection. Experiments using LPS derived from E. coli
have been shown to elicit a disproportionately strong inflammatory response (Terrando et
al, 2010). Other studies of the effects of LPS initiated neuroinflammation have more
directly implicated the molecule in LOAD pathology. LPS injected into the brains of
mouse models has been demonstrated to impair memory, promote the production of Aβ
1-42, and enhance expression of genes involved in inflammation and Aβ plaque
production (Lee et al, 2008; Gasparini et al, 2004). Infection by Cpn itself is associated
with an increased expression of enzymes associated with the formation of Aβ 1-42 and
stimulation of an inflammatory response (Al-Atrache et al, 2019; Lim et al, 2014). Thus,
there exists a clear throughline linking infection by Cpn to two well established mediators
of LOAD formation and progression; persistent neuroinflammation and Aβ plaque
formation.
1.9 Hypothesis and Specific Aims
1.9.1 Hypothesis
Chlamydia pneumoniae has been previously observed throughout the limbic system
and cortical regions in diagnosed dementia brains. The working hypothesis underlying
these studies is that the load of Chlamydia pneumoniae correlates with degree of amyloid
pathology and subsequently the severity of dementia.
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1.9.2 Specific Aims
In order to define the load of Chlamydia pneumoniae relative to the amyloid plaque
formation in the limbic system and cortical regions, immunohistochemical analysis will
be performed. The brains were selected from individuals who have been diagnosed with
dementia and/or Alzheimer’s and were compared to normal control brains donated from
the Humanity Gifts Registry (HGR).

MATERIALS
Table 2.1: Brains Used in Study
AD/Dementia
Age

Cause of Death

Gender

92

Dementia

Female

96

AD, Dementia

Female

84

AD type Dementia

Female

82

Dementia

Male

Non-AD/Dementia
Age

Cause of Death

Gender

92

Coronary Artery Disease

Female

94

COPD

Female

87

Cerebral Vascular Disease

Male

86

COPD

Male

Brain Structure

Tissue Analyzed

Area Analyzed

Anterior Hippocampus

40 tissue sections for amyloid plaques (5
tissue sections per anterior hippocampus x 8
brains)
40 tissue section for Cpn inclusions (5 tissue
sections per anterior hippocampus x 8 brain)

4.46 mm2/sections for each of the 5
tissue sections.
Total area of 89.2 mm2 for each
brain structure of a given label type

Prefrontal Cortex

40 tissue sections for amyloid plaques (5
tissue sections prefrontal cortex x 8 brains)
40 tissue section for Cpn inclusions (5 tissue
sections per prefrontal cortex x 8 brains)

4.46 mm2/sections for each of the 5
tissue sections.
Total area of 89.2 mm2 for each
brain structure of a given label type

Table 2.2: Tissue collected for analysis
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Table 2.3: Antibodies and kits utilized
Antibody

Kit

Synaptic Systems Abeta 42 antibody (Catalog# 218
703)
1:750 dilution

Abcam Mouse and Rabbit Specific HRP/DAB IHC
Detection Kit - Micro-polymer (Catalog# ab236466)

Fitzgerald Chlamydia pneumoniae antibody (Catalog#
10-C27E)
1:20 dilution

Abcam Mouse and Rabbit Specific HRP/AEC IHC Detection
Kit - Micro-polymer (Catalog# ab236467)

METHODS
3.1 Collecting Brain Tissue
A list of Human cadaver brains donated to the Human Gifts Registry (HGR) in
Pennsylvania for anatomy lab dissection was compiled with the aim of creating a group
of brains with AD/dementia and a group of brains without AD/dementia which were
controlled for age and gender. Eight brains were identified which met this criteria, four
brains in the AD category and four brains in the non-AD category (Table 2.1). From
these brains, areas of the hippocampus and the prefrontal cortex were dissected (Table
2.2). These areas were then processed via an automatic tissue processor, embedded in
paraffin, and sectioned.
3.2 Labeling
Serial slides from each brain section were stained for either Aβ plaques or Cpn.
To prepare the slides for staining, the slides were left on a warmer overnight at 55°C. The
slides were deparaffinized automatically in a Gemini Slide Stainer by Thermo Fisher
Scientific according to a pre-set lab protocol.
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3.3 Cpn Staining
Mouse and Rabbit Specific HRP/AEC IHC Detection Kit - Micropolymer
(ab236466) and the provided protocol were used (Table 2.3). Hydrogen peroxide block
was applied to the slides for 10 minutes. Antigen retrieval was then performed. 10mM
citrate buffer solution was heated via microwave until boiling. The slides were placed in
the heated citrate buffer solution for 20 minutes. The slides were washed in PBS for 5
minutes. Protein block was applied for 10 minutes. The primary antibody, Fitzgerald
Chlamydia pneumoniae antibody (10-C27E), was diluted 1:20 in PBS (Table 2.3). The
prepared antibody was incubated at room temperature for 2 hours. An unconjugated
rabbit anti-mouse antibody, referred to in the kit as mouse complement, was applied for
10 minutes, followed by Goat anti-rabbit HRP conjugate for 30 minutes and finally AEC
single solution for 5 minutes. The slides were then counterstained with Mayer's
hematoxylin for 45 seconds and rinsed in Richard Allan Scientific bluing reagent (<1.0%
<1.0% Sodium bicarbonate, magnesium sulfate, >99%water, <1% 1-Tetradecanaminium,
N,N,N-trimethyl-, bromide) for a minimum of 30 seconds and until appropriately blue.
The slides were then mounted with an aqueous mounting medium and left to dry
overnight.
3.4 Aβ Plaque Staining
Mouse and Rabbit Specific HRP/DAB IHC Detection Kit - Micropolymer
(ab236467) and the provided protocol were used (Table 2). Hydrogen peroxide block was
applied to the slides for 10 minutes, followed by protein block for 20 minutes. The
primary antibody was then prepared. Synaptic Systems Aβ42 antibody (218 703) was
diluted 1:750 in PBS (Table 2.3) and left to incubate at room temperature for 2 hours.
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Goat anti-rabbit HRP conjugate was applied for 15 minutes. 30μL of DAB chromogen
was added to 1500μL of DAB substrate. DAB solution was applied to the slides for 5
minutes. The slides were then counterstained with Mayer's hematoxylin for 45 seconds
and rinsed in a bluing solution for a minimum of 30 seconds and until appropriately blue.
The slides were then mounted with an aqueous mounting medium and left to dry
overnight.
3.5 Quantification
Digital scans of the stained slides were created using a MoticEasyScan Pro set at
40x magnification. The digital scans were opened in Nikon’s NIS-Elements AR program.
Using the native functions of the program, an appropriate sub-region of the tissue was
demarcated by an oval with an area of 4.46mm2. The shape and area of this demarcation
was held constant across all slides used in the experiment, and the specific location of the
demarcation was held constant for all hippocampal or pre-frontal tissues slides from a
given brain. Within that area, the number of Cpn inclusion bodies and Aβ plaques were
quantified. Additionally, the dimeters of each of the Aβ plaques were measured. The raw
data was then exported from NIS-Elements AR into Microsoft Excel. The ratio of Cpn
inclusions bodies and Aβ plaques were then calculated. The diameters of the Aβ plaques
were organized into three size categories as derived from criteria from Hammond et al
2010.

RESULTS
4.1 Brain Tissue Labeled for Amyloid Plaques and Chlamydial Inclusions
The non-AD brain revealed that the anti-amyloid and anti-Cpn labeling of the
plaques and inclusions in both the hippocampus and prefrontal cortex were fewer in
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number as compared to the AD/Dementia brains (Figure 4.1). The distribution of the
amyloid plaques and Cpn inclusions are not uniform, however, the majority of the
amyloid plaques and Cpn inclusions are found in relatively dense clusters separated by
large areas of little to no labeling as observed in figure 4.1. In the non-AD brain, the
amyloid plaques in the hippocampus are large, fewer in number, and have a dense core
appearance (Figure 4.1a) compared to the plaques found in the prefrontal cortex which
tend to be smaller more numerous, and diffuse (Figure 4.1c). The morphology of the Cpn
inclusions in the non-AD/dementia hippocampus (Figure 4.1b) and prefrontal cortex
(Figure 4.1d) are similar, with the labeling overall revealing inclusions with well-defined
borders. Larger more diffuse Cpn inclusions are occasionally found, but they are
uncommon and did not appear associated with a specific brain or brain region.
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4.1a

4.1b

4.1c

4.1d

Figure 4.1 Non-AD/dementia tissue from the anterior hippocampus and the prefrontal cortex
revealed amyloid plaques in the and Chlamydial inclusions within the same regions.
In both the prefrontal cortex and the hippocampus, the tissues were immunoreacted with antibodies
identifying the amyloid plaques (brown reaction) and Cpn inclusions (red reaction) 4.1a is a
representative image of a non-AD/dementia hippocampus labelled for amyloid plaques, while 4.1b
is a representative image of a serial section of the same hippocampus labelled for the presence of
Cpn. 4.1c is a representative image of a non-AD/dementia prefrontal cortex labelled for amyloid
plaques, while 4.1d is a representative image of a serial section of the same prefrontal cortex
labelled for the presence of Cpn. Images captured at 40x magnification.
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4.2a

4.2b

4.2c

4.2d

Figure 4.2
AD/dementia brain tissue from the anterior hippocampus and the prefrontal
cortex revealed amyloid plaques and Chlamydial inclusions.
In both the prefrontal cortex and the hippocampus, the tissues were immunoreacted with
antibodies identifying the amyloid plaques (brown reaction) and Cpn inclusions (red reaction)
4.2a is a representative image of an AD/dementia hippocampus labelled for amyloid plaques,
while 4.2b is a representative image of a serial section of the same hippocampus labelled for the
presence of Cpn. 4.2c is a representative image of a AD/dementia prefrontal cortex labelled for
amyloid plaques, while 4.2d is a representative image of a serial section of the same prefrontal
cortex labelled for the presence of Cpn

27

4.3a

4.3b

4.3c

4.3d

Figure 4.3
Representative micrographs of AD/dementia and non-AD/dementia tissue
from the anterior hippocampus and the prefrontal cortex immunolabeled for the presence of
GFAP.
Tissue sections of the hippocampus and prefrontal cortex from both AD/dementia and nonAD/dementia brains were labelled for the presence of GFAP (red reaction). 4.3a is a
representative image of an AD/dementia hippocampus labelled for GFAP. 4.3b is a representative
image presence of a non- AD/dementia hippocampus labelled for GFAP. 4.3c is a representative
image of an AD/dementia prefrontal cortex labelled for GFAP. 4.3d is a representative a nonAD/dementia prefrontal cortex labelled for the presence of GFAP.

In the AD/dementia brains (Figure 4.2) The density of amyloid plaques and Cpn
inclusions is notably greater in the prefrontal cortex than the hippocampus. The amyloid
plaques within the prefrontal cortex are discrete and relatively small (Figure 4.2c). The
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amyloid plaques within the hippocampus (figure 4.2a) are a mix of highly diffuse cloudlike plaques alongside relatively large plaques with a dense-core appearance. No notable
difference exists in the Cpn inclusion morphology between the AD/dementia
hippocampus (4.2b) and the AD/dementia prefrontal cortex (4.2d). The anti-Cpn labeling
in both brain regions revealed small Cpn inclusions which are uniformly distributed
throughout the tissue.
Additionally, the AD/dementia brains and non-AD/dementia brains were
immunoreacted with GFAP antibodies to determine the presence of glial cells in
association with the amyloid and Cpn inclusions in the hippocampus and prefrontal
cortex (Figure 4.3). The AD/dementia hippocampus (4.3a) and AD/dementia prefrontal
cortex (4.3c) appeared to have a greater amount of GFAP labeling as compared to the
non-AD/dementia brain hippocampus (4.3b) and non-AD/dementia prefrontal cortex
(4.3d).
4.2 Quantitative Analysis of Amyloid plagues and Chlamydial inclusions
Quantitative analysis was performed to determine the amyloid load in the
AD/dementia vs non-AD/dementia brains in the hippocampus and the prefrontal region
(Figure 4.4). The amyloid plaque count for the AD/dementia group in the hippocampus
was 1854.00±210.31 and prefrontal cortex was 3793.75±997.02. In the non-AD/dementia
group the amyloid plaque load in the hippocampus (263.00±223.06) and prefrontal cortex
(970.25±636.08) (Figure 4.4). In both the hippocampus and the prefrontal region of the
AD/dementia brains, the load of amyloid plaques was greater than in the nonAD/dementia brain. Additionally, the Cpn inclusion load in the AD/dementia
hippocampus (2272.75±395.72) and prefrontal cortex (1833.25±470.02) were greater
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Figure 4.4
Comparison of the total count means of amyloid plaques and Cpn inclusions
in the hippocampus and prefrontal cortex of AD/dementia and non-AD/dementia brains.
The x-axis represents the compiled mean counts of amyloid plaques and Cpn inclusions from the
AD/dementia or non-AD/dementia brains as organized by the brain structure examined. While the
y-axis represents the mean itself. The brown bars represent the amyloid plaque means counts
while the red bars represent the Cpn mean counts.

than the Cpn inclusion load in the non-AD/dementia hippocampus (332±220.30) and in
the prefrontal cortex (424.75±324.22).
Within the AD/dementia brains, the amyloid plaque load of the prefrontal cortex
(3793.75±997.02) is greater than the amyloid plaque load of the hippocampus
(1854±210.31). This trend also holds true for the non-AD/dementia group, in which the
amyloid plaque load of the prefrontal cortex (970.25±636.08) possesses a greater amyloid
plaque load than that of the hippocampus (263.00±223.06). The within group trend does
not hold true to the load of Cpn inclusions, however. Within the AD/dementia brains, the
load of Cpn inclusions is greater in the hippocampus (2272.75±395.72) than in the
prefrontal cortex (1833.25±470.02). Within the non-AD/dementia brains, the number of
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Figure 4.5
Comparison of the density of amyloid plaques and Cpn inclusions per mm2 in
the hippocampus and prefrontal cortex of AD/dementia and non-AD/dementia brains.
The x-axis represents the amyloid/mm2 or Cpn/mm2 counts for either the hippocampus or
prefrontal cortex of the brains investigated. The y-axis represents the number of either amyloid
plaques or Cpn inclusions per unit area. The purple bars represent the counts from the
AD/dementia brains and the green bars represent the counts from the Non-AD/Dementia brains.

Cpn inclusions is greater in the prefrontal cortex (424.75±324.22) than in the
hippocampus (332.00±220.30), however there is appreciable overlap in the standard error
of the two datasets.
The AD/dementia prefrontal cortex demonstrates a substantially greater load of
amyloid plaques (3793.75±997.02) compared to Cpn inclusions (1833.00±470.02). The
non-AD/dementia prefrontal cortex also demonstrates a significantly greater load of
amyloid plaques (970.25±636.08) compared to Cpn inclusions (424.75±324.22). In
contrast, the AD/dementia hippocampus demonstrates a greater load of Cpn inclusions
(2272.75±395.72) than amyloid plaques (1854.00±210.31). The amyloid plaque to Cpn
load difference in the hippocampus is less than the difference observed in either the
AD/dementia or non-AD/dementia prefrontal cortex. The non-AD/dementia hippocampus
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shows a greater load of Cpn inclusions (332.00±220.30) than amyloid plaques
(263.00±223.06), however there is major overlap in the standard error between the Cpn
inclusion load and amyloid plaque load.
The density of amyloid plaque is greater in the AD/dementia hippocampus
(83.13/mm2) and AD/dementia prefrontal cortex (170.12/mm2) compared to the amyloid
plaque density in the non-AD/dementia hippocampus (11.79±10.00/mm2) and nonAD/dementia prefrontal cortex (43.51/mm2), respectively (Figure 4.5). Similarly, the Cpn
inclusion density is greater in the AD/dementia hippocampus (101.92/mm2) and
AD/dementia prefrontal cortex (82.21/mm2) than the Cpn inclusion density in the nonAD/dementia hippocampus (14.89/mm2) and non-AD/dementia prefrontal cortex
(19.05/mm2).
In addition to total counts and density, the amyloid plaques were further
organized into three diameter ranges; 0-24.9 μm, 25-49.9 μm, and 50+ μm. Figure 4.6
shows the frequency of amyloid plaques within each of these categories. As this figure is
derived from the same dataset as the total counts, the data follows the amyloid plaque
load trend established in figure 4.1. The AD/dementia brains demonstrate a greater
amyloid plaque burden than the non-AD/dementia brains in both the hippocampus and
prefrontal cortex regions across all three diameter ranges. For the AD/dementia brains,
the prefrontal cortex demonstrates a greater amyloid plaque load than the hippocampus in
the 0-24.9 μm and 25-49.9 μm categories. The 50+ μm category for both the
AD/dementia prefrontal cortex and AD/dementia hippocampus are similar, however.
This same trend can be observed within the non-AD/dementia brains as well. The nonAD/dementia prefrontal cortex demonstrates a greater amyloid plaque load than the nonAD/dementia hippocampus in the 0-24.9 μm and 25-49.9 μm categories, while the 50+
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Figure 4.6
Distribution of amyloid plaques across three diameter ranges in the
hippocampus and prefrontal cortex of AD/dementia and non-AD/dementia brains.
The x-axis represents the amyloid plaque diameter categories from the AD/dementia and nonAD/dementia brains organized by the brain structure examined. The y-axis represents the total
number of plaques within each diameter category. The blue bars represent the number of plaques
which fell within a diameter range of 0-24.9 μm, the green bars represent the total plaques which
fell into the 25-49.9 μm diameter range, and the yellow bars represent the total number of plaques
which fell into the 50+ μm diameter range. These diameter ranges where derived from criteria
established by Hammond et al, 2010.

counts are similar. The relative amounts of plaques per diameter category appear
consistent across all groups, with the majority of plaques falling within the 0-24.9 μm
category, followed by the 25-49.9 μm, and finally the 50+ μm category.
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Figure 4.7
Distribution of amyloid plaques across three diameter ranges as a percentage
of total plaque load in the hippocampus and prefrontal cortex of AD/dementia and nonAD/dementia brains.
The x-axis represents the total amyloid plaque diameter ranges from the AD/dementia and nonAD/dementia brains organized by the brain structure examined. The y-axis represents the
percentage of plaques which make up each of the three diameter ranges. The blue bars represent
the percentage of plaques which fell within a diameter range of 0-24.9 μm, the green bars
represent the percentage of plaques which fell into the 25-49.9 μm diameter range, and the yellow
bars represent the percentage of plaques which fell into the 50+ μm diameter range.

AD/dementia and non-AD/dementia brains, elucidates this trend (Figure 4.7). The 0-24.9
μm diameter category accounts for 57% of the plaques in the AD/dementia hippocampus,
64% of the plaques in the AD/dementia prefrontal cortex, 55% of the non-AD/dementia
hippocampus, and 63% of the non-AD/dementia prefrontal cortex. The 25-49.9 μm
accounts for 37% of the plaques in the AD/dementia hippocampus, 33% of the plaques in
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Figure 4.8
Comparison of the amyloid plaque and Cpn inclusion in the hippocampus and
prefrontal cortex of the non-AD/dementia brains by COD.
The x-axis represents each of the non-AD/dementia brains as identified by the COD provided by
the humanity gifts registry. Furthermore, under each COD identifier is a secondary x-axis which
identifies a grouping of bars as representing data from either the hippocamus or prefronal cortex
of the brain in question. The y-axis represents the number of either amyloid plaques or Cpn
inclusions. The brown bars represent the amyloid plaque counts while the red bars represent the
Cpn inclusion counts.

the AD/dementia prefrontal cortex, 37% of the non-AD/dementia hippocampus, and 34%
of the non-AD/dementia prefrontal cortex. And finally, the 50+ μm category accounts for
accounts for 6% of the plaques in the AD/dementia hippocampus, 3% of the plaques in
the AD/dementia prefrontal cortex, 8% of the non-AD/dementia hippocampus, and 3% of
the non-AD/dementia prefrontal cortex.
Nearly all the amyloid plaque and Cpn inclusion counts for the non-AD/dementia
brains were derived from two brains (Figure 4.8). Specifically, the brain with cerebral
vascular disease were listed as the cause of death (COD) and the brain with coronary
artery disease listed as the COD. For the cerebral vascular disease brain, the load of
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amyloid plaques (1099) and the load of Cpn inclusions (330) in the prefrontal cortex is
greater than the load of amyloid plaques (927) or Cpn inclusions (70±54.94) in the
hippocampus. For the coronary artery disease brain, the load of amyloid plaques (2722)
and the load of Cpn inclusions (1269) in the prefrontal cortex is greater than load of
amyloid plaques (120) or Cpn inclusions (930) in the hippocampus. For the COPD brain,
the amyloid plaque and Cpn inclusion counts are 0. For the stroke/dysphagia brain, load
of amyloid plaques (60) in the prefrontal cortex is greater than the load of amyloid
plaques in the hippocampus (5). The Cpn inclusion counts for the stroke/dysphagia for
both the prefrontal cortex and hippocampus are 0.
The prefrontal cortex of the coronary artery disease brains shows a greater
amyloid plaque load (2722) and Cpn inclusion load (1269) than amyloid plaque load
(1099) or Cpn inclusion load (330±6.12) of the prefrontal cortex of the cerebral vascular
disease brain. The amyloid plaque load in the hippocampus of the coronary artery disease
brain (120) is less than the amyloid plaque load in the hippocampus of the cerebral
vascular disease brain (927). The Cpn inclusion load (1269) in the hippocampus of the
coronary artery disease brain is greater than the Cpn inclusion load (70) in the
hippocampus of the cerebral vascular disease brain.
Among the AD/dementia brains, the load of amyloid plaque and the load of Cpn
inclusions does not seem to vary with COD (Figure 4.9). The two brains with AD listed
as COD (AD, Dementia; AD Type Dementia) and the two brains with only dementia
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Figure 4.9
Comparison of the amyloid plaque and Cpn inclusion loads in the
hippocampus and prefrontal cortex of the AD/dementia brains by COD.
The x-axis represents each of the AD/dementia brains as identified by the COD provided by the
humanity gifts registry. Furthermore, under each COD identifier is a secondary x-axis which
identifies a grouping of bars as representing data from either the hippocamus or prefronal cortex of
the brain in question. The y-axis represents the total number of either amyloid plaques or Cpn
inclusions. The brown bars represent the amyloid plaque counts while the red bars represent the
Cpn inclusion counts.

listed as COD (Dementia Brain 1; Dementia Brain 2) contributed equally to the total
counts. For the AD, dementia brain, the load of amyloid plaques is greater in the
prefrontal cortex (5940±38.18) than the load of amyloid plaques in the hippocampus
(1884), while the load of Cpn inclusions is lesser in the prefrontal cortex (1606) than in
the hippocampus (2618). Within the AD dementia hippocampus itself, the load of Cpn
inclusions (2618) is greater than the load of amyloid plaques (1884). While, within the
AD/dementia prefrontal cortex, the load of Cpn inclusions (1606) is less than the load of
amyloid plaques (5940).
For the AD type dementia brain, the load of amyloid plaques (2423) and Cpn
inclusions (1736) in the hippocampus is greater than the load of amyloid plaques (1662)
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and Cpn inclusions (1243) in the prefrontal cortex. Within the AD type dementia brain
hippocampus, the load of amyloid plaques (2423) is greater than the load of Cpn
inclusions (1736). This is also true of the prefrontal cortex within the AD type dementia
brain, with the load of amyloid plaques (2423) being greater than the load of Cpn
inclusions (1243).
For the dementia brain 1, the load of amyloid plaques in the prefrontal cortex
(4965) is greater than the load of amyloid plaques in the hippocampus (1439). The load
of Cpn inclusions in the dementia brain 1 prefrontal cortex (3221) is equal to the load of
Cpn inclusions in the dementia brain 1 hippocampus (3221). Within the dementia brain 1
hippocampus the load of amyloid plaques (1439) is less than the load of Cpn inclusions
(3221). Whereas within the dementia brain 1 prefrontal cortex the load of amyloid
plaques (4965) is greater than the load of Cpn inclusions (3221).
For the dementia brain 2 the load of amyloid plaques in the prefrontal cortex
(2608) is greater than the load of amyloid plaques in the hippocampus (1670). The load
of Cpn inclusions in the dementia brain 2 prefrontal cortex (1263) is less than the load of
Cpn inclusions in the dementia brain 2 hippocampus (1516). Within the dementia brain 2
prefrontal cortex the load of amyloid plaques (2608) is greater than the load of Cpn
inclusions (1263). Within the dementia brain 2 hippocampus the load of amyloid plaques
(1670) is greater than the load of Cpn inclusions (1516).

DISCUSSION
5.1 Amyloid Pathology and Characteristics
Amyloid plaque and Cpn immunoreactivity were observed in both the
AD/dementia and non-AD/dementia brains. Notably, the morphology of amyloid plaques
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varied between the AD/dementia and non/AD dementia brains as well as between the
hippocampus and prefrontal cortex sections. Amyloid plaques are known to occur in a
range of morphologies (Dickinson & Vickers, 2001, Thal et al. 2006), thus this variation
is not indicative of any error in the immunolabeling or quantification procedure. Previous
studies on the formation and progression of amyloid plaques in AD and other
amyloidopathies have proposed a three-tiered morphology classification system which
represents progressive stages of plaque maturation (Rohr et al, 2020; Ji,et al, 2018;
Tagliavini et al, 1988). Under this system, the least mature amyloid plaque is referred to
as diffuse, followed by compact, and finally the mature dense core plaque. Diffuse
plaques can be identified by their thin, amorphous, cloud-like appearance and lack of
clear borders or identifiable center point. Compact plaques appear uniformly dense, have
well defined borders, and are likely to appear circular or ovoid in shape. Dense core
plaques are identified by the presence of a particularly dense center point which is
surrounded by a halo of distinctly less dense but still well-defined immunolabeling.
These plaques are also usually circular or ovoid in shape.
The amyloid plaques found within the AD/dementia brains were overwhelmingly
of the diffuse and compact type. The load of plaques in the prefrontal cortex of the
AD/dementia brains noticeably skewed toward compact plaques, while the hippocampus
was more likely to show an equal distribution of diffuse and compact amyloid plaques.
Dense core plaques were still present in the AD/dementia brains, but at a dramatically
lower rate than the other two morphologies. Additionally, dense core plaques were more
likely to be found in the hippocampus of the AD/dementia brains than in the prefrontal
cortex. The non-AD/dementia brain primarily contained compact and dense core amyloid
plaques. Unlike the AD/dementia brains, in which all three plaque morphologies were
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present to some degree, the non-AD/dementia brains showed little to no diffuse amyloid
plaque morphology in either brain section. The hippocampus of the non-AD/dementia
brains primarily showed dense core plaques with the occasional presence of compact
plaques. Whereas the prefrontal cortex of the non-AD/dementia brains primarily showed
compact plaques and few dense core plaques. In general, the hippocampus is more likely
to contain dense core plaques and the prefrontal cortex is more likely to contain compact
plaques. It should also be noted that although dense core plaques were identified as one
of the primary plaque morphologies observed in the non-AD/dementia brains, this does
not indicate that the non-AD/dementia brains contain more dense core plaques than the
AD/dementia brains. This description simply indicates that of the plaques that were
observed in the non-AD/dementia brains, many were dense cored. Furthermore,
considering the greater total load of amyloid plaques found in AD/dementia brains
compared to the non-AD/dementia brains, it is highly likely that the AD/dementia brains
contain more dense core plaques than the non-AD/dementia brains.
Each of the three plaque morphologies are associated with a specific biochemical
composition (Thal et al. 2006, Rohr et al. 2020). Diffuse plaques are primarily composed
of low concentrations of oligomeric and protofibrillar Aβ42. Compact plaques are
primarily composed of high concentrations of oligomeric and protofibrillar Aβ42 as well
as varying levels of mature Aβ42 fibrils. The core of a dense core plaque is composed of
tightly packed mature Aβ42 fibrils while the halo is composed of low concentration of
oligomeric and protofibrillar Aβ42 similar to that of the diffuse plaques (Rohr et al.
2020). This change in amyloid plaque makeup observed from diffuse to dense primarily
validates the notion that each category represents progressive stages of plaque maturation
(Rohr et al. 2020). However, the specific makeup that characterizes each plaque
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morphology additionally has interesting implications for the pathology of AD. As
mentioned previously, the Aβ42 mature fibrils and the Aβ42 oligomers are known to
exert a cytotoxic effect. However, the Aβ42 oligomers are considered the main cause of
the neurotoxic damage seen in AD (Tamango et al, 2018; Verma et al, 2015). Thus, it is
possible that a greater load of diffuse and compact plaques represents greater neurotoxic
stress on the brain. This assumption would follow from the IHC results of this study
which demonstrated that AD/dementia brains carry a high load of both diffuse and
compact plaques, and thus a high load of the neurotoxic Aβ42 oligomer. Furthermore, as
diffuse and compact plaques likely represent less mature and thus more recently formed
amyloid plaques, it is possible that an abundance of these plaque morphologies represent
a rapid rate of new plaque formation as might be expected from the positive feedback
loop of plaque formation caused by secondary nucleation likely to occur in later stage AD
(Verma et al, 2015)
5.2. Cpn pathology and morphology
Immunolabeling for the presence of Cpn revealed two patterns of Cpn
immunoreactivity. The first pattern of Cpn immunoreactivity were punctate inclusions.
This pattern represented the majority of inclusions observed in every brain where Cpn
was present. Previous research has suggested that these punctate inclusions are indicative
of the elementary body phase of the Cpn lifecycle (Hammond et al, 2010; Hybiske &
Stevens, 2007). The second pattern of Cpn immunoreactivity were larger cloud-like
inclusions. These inclusions were significantly less common than the punctate elementary
bodies and occurred primarily in the AD/dementia brains. The hippocampus and
prefrontal cortex of the AD/dementia brains did not display a noticeable difference in the
frequency of these cloud-like inclusions. Previous research has suggested that these
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inclusions represent factors such as lipopolysaccharides that have been secreted by Cpn
(Hammond, 2010; Hybiske & Stevens, 2007), however no literature was found that has
associated this labeling pattern with a particular life cycle phase or specific behavior of
Cpn. As these cloud-like inclusions primarily occurred in the AD/dementia brains it is
possible that this labeling pattern is indicative of a more active Cpn infection. For
example, like many obligate intracellular bacteria, Cpn relies on the secretion of effector
proteins, such as CPn0572, CPn0677, and CPn0678, to prime the host cell membrane for
entry (Hansch, 2020). The cloud of immunoreactivity may represent these secreted
effector proteins, and thus show a Cpn bacterium in the process of entering a new host
cell.
5.3 Amyloid Plaques and Cpn Inclusion Counts
The primary questions investigated by this study were, firstly, if amyloid plaque
load correlates with Cpn inclusion load, and secondly, if there is a difference in amyloid
plaque and Cpn inclusion load between AD/dementia and non-AD/dementia brains. It has
been well established in the literature that AD is associated with an increased load of
amyloid plaques (Barage et al, 2015). Additionally, previous research regarding the
relationship between AD and Cpn has suggested that AD status is correlated with the
presence of Cpn (Balin et al, 1998; Bu et al, 2015; Contini et al, 2010; Ecemis et al, 2010;
Hammond et al, 2010; Itzhaki et al, 2004; Little et al, 2004; Little et al, 2014; Lim et al,
2014). Thus, it follows that the load of Cpn inclusions likely positively correlates with the
load of amyloid plaques and furthermore the load of amyloid plaques and Cpn inclusions
will be greater in the AD/dementia brains than in the non-AD/dementia brains. The total
counts recorded in this study confirm these assumptions. The results showed a strong
positive correlation between the load of amyloid plaques and Cpn inclusions, regardless
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of AD/dementia or non-AD/dementia status. Additionally, the load of amyloid plaques
and Cpn inclusions was substantially higher in the AD/dementia brains for both sections
compared to the non-AD/dementia brains.
The total counts additionally revealed an interesting relationship between the load
of amyloid plaques and Cpn inclusions within the hippocampus and prefrontal cortex
which was independent of AD/dementia or non-AD/dementia status. The prefrontal
cortex of both the AD/dementia and non-AD/dementia brains displayed a higher load of
amyloid plaques than Cpn inclusions. The difference between the load of amyloid
plaques and Cpn inclusions was substantial, with AD/dementia prefrontal cortex showing
2.07x more amyloid plaques than Cpn and the non-AD prefrontal cortex showing 2.23x
more amyloid plaques than Cpn. The hippocampus on the other hand shows a greater
load of Cpn than amyloid plaques. The difference between the load of amyloid plaques
and Cpn inclusions in the hippocampus was not as extreme as in the prefrontal cortex.
The AD/dementia hippocampus showed 1.23x more Cpn inclusions than amyloid plaques
while the non-AD/dementia hippocampus showed 1.26x more Cpn inclusions than
amyloid plaques. However, there is significant overlap in the standard error between the
Cpn inclusion counts and amyloid plaques counts in the non-AD/dementia hippocampus
so the difference within the non-AD/dementia hippocampus may not be meaningful. The
consistent relationship between the relative loads of amyloid plaque and Cpn inclusions
across AD/dementia and non-AD/dementia brain structures is potentially vital evidence
towards the infection hypothesis of AD, as it demonstrates that Cpn may be present from
the earliest stages of AD. This reduces the likelihood that the increased presence of Cpn
observed in this, and previous studies is the result of a third variable, such as a
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compromised CNS immunity or a damaged blood brain barrier which may occur in the
later stages of AD.
5.4 Conclusion
This study was the first to quantify an infection with Chlamydia pneumoniae and
production of amyloid plaques. The hypothesis underlying this study is that load of
Chlamydia pneumoniae correlates with degree of amyloid pathology within the limbic
system. The results provide strong evidence demonstrating this correlation. The load of
Cpn consistently correlated with load of amyloid plaques in the regions of the brain
anaylzed. Additionally, the load of both amyloid plaques and Cpn was markedly higher
in the brains where AD/dementia was recorded on the death certificate compared to the
brains where a COD other than AD/dementia was recorded. Prior research has suggested
that Cpn may act as trigger for the formation of amyloid plaques through the initiation of
an inflammatory response (Al-Atrache et al., 2019, Lim et al, 2014; Little et al, 2014;
Little et al, 2004; Hammond et al, 2006; Ou et al, 2021). While the results of this study
cannot confirm whether this is indeed the case, nor can this study even claim a causal
relationship between infection and AD/dementia, the results further validate the findings
of these previous studies by demonstrating the connection between Cpn and amyloid in
humans with AD/dementia diagnoses.
Previous research has also suggested that Cpn enters the CNS via an olfactory
route of infection (Little et al, 2014; Little et al, 2005; Itzhaki et al, 2004). The body of
work demonstrating this connection was a primary motivator for specifically
investigating the limbic system for Cpn and AD pathology. Unlike other afferent
pathways which first synapse at the thalamus, the olfactory nerve synapses directly to the
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limbic system. Thus, assuming that Cpn is a possible trigger for the formation of amyloid
plaques and assuming that Cpn enters the CNS via the olfactory pathway then the
olfactory blub and related limbic structures should be among the first areas to show AD
pathology. This is indeed the case, with the earliest neural damage in LOAD occurring in
the lateral entorhinal cortex followed by damage in the hippocampal formation (ChristenZaech et al, 2003; Mann et al 1988; Balin & Hudson, 2020). The result of this study may
also serve to validate these findings. Firstly, the hippocampus of both the AD/dementia
and non-AD/dementia brains revealed a higher frequency of amyloid plaques of mature
morphology compared to the corresponding prefrontal cortices. Within the AD/dementia
brain, amyloid plaques of compact morphology predominated alongside a less common
but still appreciable presence of dense core plaques. The non-AD/dementia hippocampus
meanwhile displayed primarily dense core plaques alongside some compact plaques. This
difference in morphology may possibly provide evidence that plaques have been forming
in the hippocampus for a longer period of time than in the prefrontal cortex, and thus that
Cpn may have been present for longer. Secondly, the load of Cpn inclusions found within
the AD/dementia hippocampus was greater than the load found with the prefrontal cortex.
This again may be evidence that within these brain Cpn infection occurs in the
hippocampus earlier than in the prefrontal cortex.
This study additionally serves to validate the use of the Human Gifts Registry
(HGR) as a viable and useful source of experimental tissue. The HGR is non-profit
agency of the Commonwealth of Pennsylvania concerned primarily with the donation and
distribution of bodies to all medical and dental schools in the state for research and
teaching purposes (Human Gifts Registry, 2022). As the HGR donates whole cadavers to
institutions, it provides researchers with a high degree of control and flexibility. For
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example, every brain used in this study was harvested from cadavers donated by the
HGR. As such, this allowed the researchers to oversee nearly every step of the
experimental process, from dissection to formalin fixation, and paraffin embedding.
Furthermore, as the entire brain was on hand and accessible to the researchers, changes or
additions to the experiment could be implemented with ease and at the researcher’s
convenience. However, most vitally, this study demonstrated that the diagnostic
information provided by HGR on the donor is accurate enough to use in experimentation.
The only information provided by HGR regarding the cadavers is age, gender, race, and
COD. No further medical records or history are provided. Thus, this experiment relied
entirely on COD to create the AD/dementia and non-AD/dementia groups. Since the
results of this study showed a substantially higher load of amyloid plaques in the
AD/dementia brains compared to the non-AD/dementia brains the COD provided by the
HGR for each brain was likely accurate as a COD.
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